Loudon China distinguishes itself from other management consulting firms through the perfect combination of western pharmaceutical management knowledge, a rich healthcare data base in China and the integrated resources of regulatory, medical, marketing, financial specialist and statisticians. We have provided a range of quality services to both domestic companies and international companies (local subsidiaries head offices) of life science companies.
Given the China potential of life science industry, the large size of the market and fast growth in last decades, multinational companies have already put China on the map with global development and launch programs.
Medium size overseas’ companies some times have good product portfolio or pipeline, but the business size is not big enough to give the confidence to them to build up their own entity in China. An entry strategy project with reviewing of scenarios will be very helpful for them to choose the right business models to maximize its opportunities and control its business risks on upfront investment.
With its expertise of regulatory affair service, marketing research and clinical trial service, LFE is able to provide market entry strategy consulting service in the following fields.
Product leads from local market or head offices, decisions to be taken upon analysis of U & A of the market, assessment of product competitive strength, synergies of clients products, sales and marketing investment, up take of sales and key assumptions, sales and P & L forecast.
Project consist a few or all parts of the following analysis,
Strategic focus of TAs and portfolio management with optimal product mix are key success factors of pharmaceutical industry for both research based pharmaceutical companies and generic companies.
For generic company, plan of its portfolio and pipeline in China, create synergy and improvement of efficiency of sales force, establish brand equity for high quality generics.
For research based pharmaceutical companies, strategic planning in China of its competitive advantages, efficiency of operation, field force optimization, maximize the capture of market opportunity and return of investment.
Loudon China helps the clients to develop plan to focus on strategic TAs and MOAs (mode of actions), and identify opportunities to license in or acquire in these areas.
To maximize the market opportunities and ROI, keep competitiveness against competitors in short term and long term, give the best supports to internal and external stakeholders.
Loudon China has provided consulting services to international companies programs of excellence of operations. Our case experience Includes but not limits to the following:
To refine the allocation and activities, to enhance market status by a competitive pricing strategy, to be transparent, to maximize market opportunities or ROI, to cope the product pricing strategy adjustment.
Key steps of the value chain, key stakeholders, prices and margin allocation, pull and back scenarios with options of reallocation without or with our product price deduction.
For Rx products, the key stakeholders are pharma or device companies, custom, importer, distributor, NDRC and provincial procurement officials, hospital, physicians and patients.
For OTC products, the key stakeholders are pharma or device companies, custom, importer, distributor, pharmacies, pharmacists and consumers.
*If any questions, please contact our client service person.
James Th. Loudon
Tel: +86-15221018640
Email: loudon@loudon-research.com
Mark Wagstaff
Tel: +86-13501764474
Email: mark.wagstaff@loudon-research.com
Copyright © Loudon Far East All Rights Reserved
沪ICP备05030935